Top-line results from Zhaoke Ophthalmology's (HKG:6622) phase III clinical trial of its NVK002 showed "strong" safety and high patient compliance, according to a Wednesday bourse disclosure.
NVK002 is indicated for the treatment of myopia progression in Chinese children and adolescents.
The two-year trial involved 18 centers and enrolled 777 patients.
Shares of the ophthalmic pharmaceutical company closed over 2% higher on Wednesday.
Price (HKD): $1.36, Change: $+0.030, Percent Change: +2.26%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。